Aspire Biopharma Holdings Inc Financials

Aspire Biopharma Holdings Inc (ASBP) reported $6K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Aspire Biopharma Holdings Inc (ASBP) reported a net income of -$24.5M in fiscal year 2025, with a net profit margin of -397868.5%.

Aspire Biopharma Holdings Inc (ASBP) reported diluted earnings per share of $-16.38 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aspire Biopharma Holdings Inc (ASBP) had a gross margin of -1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Aspire Biopharma Holdings Inc (ASBP) had an operating margin of -314501.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Aspire Biopharma Holdings Inc (ASBP) had a net profit margin of -397868.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Aspire Biopharma Holdings Inc (ASBP) generated -$4.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Aspire Biopharma Holdings Inc (ASBP) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Aspire Biopharma Holdings Inc (ASBP) invested $924K in research and development during fiscal year 2025.

Aspire Biopharma Holdings Inc (ASBP) had 5M shares outstanding as of fiscal year 2025.

Aspire Biopharma Holdings Inc (ASBP) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Aspire Biopharma Holdings Inc (ASBP) had a debt-to-equity ratio of -1.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Aspire Biopharma Holdings Inc (ASBP) had a return on assets of -1865.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Aspire Biopharma Holdings Inc (ASBP) had $4K in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Aspire Biopharma Holdings Inc (ASBP) has negative shareholder equity of -$6.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Aspire Biopharma Holdings Inc (ASBP) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Aspire Biopharma Holdings Inc (ASBP) has an earnings quality ratio of 0.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Aspire Biopharma Holdings Inc (ASBP) has an interest coverage ratio of -2.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.